Marta Escorihuela

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

Journal: Nature cancer

Published: May 29, 2026

Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.

Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: April 27, 2024

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors.

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors.

Journal: Nature communications

Published: December 04, 2023

LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells.

LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells.

Journal: The FEBS journal

Published: June 01, 2023

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 16, 2022

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

Journal: Nature cancer

Published: July 14, 2022

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Journal: Cancer research

Published: March 18, 2022

The target antigen determines the mechanism of acquired resistance to T cell-based therapies.

The target antigen determines the mechanism of acquired resistance to T cell-based therapies.

Journal: Cell reports

Published: November 02, 2021

MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.

MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.

Journal: Cancer research communications

Published: October 26, 2021

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation.

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation.

Journal: Nature communications

Published: October 28, 2020

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.

Journal: Cancers

Published: February 21, 2020

p95HER2-T cell bispecific antibody for breast cancer treatment.

p95HER2-T cell bispecific antibody for breast cancer treatment.

Journal: Science translational medicine

Published: January 29, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026